Make an Inquiry
Accelerating Severe Combined Immunodeficiency Disease Drug Development

Severe combined immunodeficiency disease (SCID) presents a formidable therapeutic challenge, with its profound impact on immune function and the urgent need for innovative treatments. Protheragen stands as a specialized partner in SCID drug development, leveraging deep scientific expertise to advance novel therapeutics for this life-threatening condition. Protheragen offers a comprehensive suite of preclinical services, encompassing target validation, lead optimization, in vitro and in vivo efficacy assessments, and IND-enabling studies. Our integrated approach is supported by advanced platforms for molecular and cellular analysis, robust animal models, and state-of-the-art bioanalytical capabilities. Stringent adherence to global regulatory standards ensures the generation of high-quality, translatable data, streamlining the path from discovery to clinical development. With a proven track record in immunodeficiency research, Protheragen’s multidisciplinary team is dedicated to overcoming the complexities of SCID drug development. Our commitment to scientific excellence and operational efficiency positions us to accelerate therapeutic breakthroughs, ultimately enabling the delivery of transformative solutions for patients affected by SCID.

What is Severe Combined Immunodeficiency DiseaseTargets for Severe Combined Immunodeficiency DiseaseDrug Discovery and Development ServicesWhy Choose Us

What is Severe Combined Immunodeficiency Disease

Severe Combined Immunodeficiency Disease (SCID) is a group of rare, life-threatening genetic disorders characterized by profound defects in both cellular and humoral immunity. SCID arises from mutations in genes critical for the development, signaling, or survival of lymphocytes, most commonly affecting T cells and variably impacting B and natural killer (NK) cells. The most prevalent forms include X-linked SCID due to IL2RG mutations, adenosine deaminase deficiency (ADA-SCID), and autosomal recessive variants such as JAK3, IL7R, and RAG1/2 deficiencies. These genetic defects disrupt essential pathways for immune cell maturation or function, resulting in a severely compromised adaptive immune system and extreme vulnerability to infections. Clinically, SCID presents in early infancy with recurrent, severe, and often opportunistic infections, persistent diarrhea, failure to thrive, and poor responses to vaccinations. Laboratory findings typically reveal marked lymphopenia, especially of T cells, and low immunoglobulin levels. Diagnosis is established through immunological assessment, flow cytometry of lymphocyte subsets, and confirmatory genetic testing. Early detection, often via newborn screening, is crucial for survival. Treatment options include hematopoietic stem cell transplantation, which offers a potential cure, and enzyme replacement therapies such as elapegademase or pegademase for ADA-SCID. Prompt intervention is essential to prevent fatal complications and improve long-term outcomes.

Launched Drugs

Generic Name CAS Registry Number
elapegademase (Rec INN; USAN); elapegademase-lvlr 1709806-75-6
pegademase (Rec INN) 130167-68-9

Learn More

Targets for Severe Combined Immunodeficiency Disease

Severe Combined Immunodeficiency Disease (SCID) arises from defects in key molecular targets essential for lymphocyte development and immune function. The most prominent targets include the Interleukin 2 Receptor Subunit Gamma (IL2RG), Interleukin 7 Receptor (IL7R), and Janus Kinase 3 (JAK3), all of which are critical for cytokine receptor signaling necessary for T, B, and NK cell maturation. Additionally, genes involved in V(D)J recombination and DNA repair—such as Recombination Activating Genes RAG1 and RAG2, and DNA Cross-Link Repair 1C (DCLRE1C/Artemis)—are vital for generating diverse antigen receptors on lymphocytes. Another key target, Adenosine Deaminase (ADA), is central to purine metabolism; its deficiency leads to the toxic accumulation of metabolites, resulting in lymphocyte apoptosis. Disruption of these targets manifests as profound immunodeficiency, characterized by absent or dysfunctional T, B, and sometimes NK cells. Therapeutic strategies for SCID have evolved by targeting these molecular defects. Gene therapy has shown curative potential for IL2RG, ADA, and Artemis deficiencies, offering long-term immune reconstitution. Enzyme replacement therapy with PEG-ADA is effective for ADA deficiency, while hematopoietic stem cell transplantation remains the standard for various genetic forms of SCID. Advances in molecular diagnostics have enabled precise identification of the underlying defect, guiding personalized interventions. Ongoing research aims to refine gene-editing approaches and improve outcomes, underscoring the pivotal role of these targets in both understanding SCID pathogenesis and developing transformative therapies.

Learn More

Drug Discovery and Development Services

In Vitro Efficacy Testing ServicesIn Vivo Model DevelopmentPK/PD Study ServicesIn Vivo Toxicity Assessment ServicesBiomarker Analysis Services
In Vitro Efficacy Testing Services

Online Inquiry

Our In Vitro Efficacy Testing Service accelerates SCID drug discovery by offering robust screening and characterization platforms targeting key proteins such as IL2RG, ADA, JAKs, and KIT. Utilizing advanced methodologies—including bioluminescent, chemiluminescent, ELISA, FRET, and fluorescent assays—we assess compound efficacy, mechanism of action, and pathway modulation. We provide precise quantification of pharmacological parameters (EC-50, IC-50, Ki) to support data-driven candidate selection and optimization. Our tailored approach ensures high sensitivity and flexibility, enabling rapid evaluation of therapeutic potential for genetic and immunological deficiencies characteristic of Severe Combined Immunodeficiency Disease.

Adenosine A2A Receptor Adenosine A2B Receptor
Atp Binding Cassette Subfamily B Member 11 Janus Kinase 1
Janus Kinase 2 Janus Kinase 3
Kit Proto-Oncogene, Receptor Tyrosine Kinase Protein Tyrosine Phosphatase Receptor Type C

Learn More

Why Choose Us

Choosing Protheragen for your Severe Combined Immunodeficiency Disease (SCID) drug development needs means partnering with a team that brings unparalleled expertise and dedication to this challenging field. At Protheragen, our specialized knowledge in SCID research and drug development is supported by a multidisciplinary team of scientists and clinicians who are deeply committed to advancing innovative therapies for this rare disorder. Utilizing advanced technology platforms and state-of-the-art facilities, we ensure that every stage of preclinical drug development is conducted with the highest level of precision and efficiency. Protheragen has established a strong track record of delivering reliable and effective preclinical services, consistently meeting the expectations of our clients and partners. Our rigorous adherence to quality standards and strict regulatory compliance guarantees that all projects are executed with integrity and in accordance with global best practices. Above all, Protheragen is driven by a genuine commitment to advancing SCID therapeutics, striving to bring hope and improved outcomes to patients and families affected by this life-threatening condition. Partner with Protheragen and experience the professionalism and reliability that set us apart in the field of SCID drug development.

FAQs for Our Services

Q: What are the primary preclinical research challenges specific to Severe Combined Immunodeficiency Disease (SCID)?

A: SCID presents unique preclinical research challenges due to its genetic and immunological complexity. Developing relevant animal models that accurately recapitulate human SCID phenotypes is critical but can be technically demanding. Additionally, the rarity of the disease limits the availability of patient-derived samples for in vitro studies. Our company addresses these challenges by leveraging advanced gene-editing techniques to create precise SCID animal models and by establishing collaborations with clinical centers to access valuable biological materials.

Q: What are the key regulatory considerations for preclinical drug development targeting SCID?

A: Given SCID's classification as a rare and life-threatening disease, regulatory agencies such as the FDA and EMA may offer expedited pathways, including orphan drug designation and fast-track status. However, rigorous preclinical safety and efficacy data are still required. Our team has extensive experience in designing GLP-compliant studies and preparing comprehensive regulatory submissions tailored to the unique requirements of SCID therapies, ensuring a smooth transition from preclinical to clinical development.

Q: What technical aspects should be considered in preclinical research for SCID drug candidates?

A: Preclinical research for SCID requires specialized expertise in immunology, gene therapy, and molecular biology. Key technical considerations include selecting appropriate in vivo and in vitro models, optimizing delivery systems for gene or cell therapies, and developing sensitive assays to assess immune reconstitution and off-target effects. Our integrated platform offers end-to-end technical support, from model selection and assay development to advanced analytics for immunological endpoints.

Q: What are the typical timeline and cost considerations for preclinical SCID drug development?

A: Preclinical development for SCID therapeutics typically spans 18-30 months, depending on the complexity of the drug modality (e.g., small molecules, biologics, or gene therapies) and regulatory requirements. Costs can vary widely, ranging from $2 million to $10 million or more, especially for gene or cell therapy approaches that require specialized manufacturing and testing. We provide customized project management and transparent budgeting to optimize timelines and control costs while maintaining scientific rigor.

Q: What are the critical success factors in preclinical drug development for SCID?

A: Success in preclinical SCID drug development hinges on several factors: robust disease modeling, comprehensive safety and efficacy profiling, early engagement with regulatory agencies, and seamless integration of multidisciplinary expertise. Our company’s strengths lie in our proven track record with rare disease models, our regulatory knowledge, and our ability to rapidly adapt to emerging scientific and regulatory trends, all of which maximize the likelihood of successful clinical translation.

Make an Inquiry
Important Links
Get in Touch with Us

Copyright © 2026 Protheragen. All rights reserved.